The clinical significance of axillary sentinel lymph node biopsy in different clinical stages breast cancer patients after neoadjuvant chemotherapy View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2013-11

AUTHORS

Juan Xu, Xinhong Wu, Yaojun Feng, Feng Yuan, Wei Fan

ABSTRACT

ObjectiveWe aimed to study the success and false negative rate of sentinel lymph node biopsy (SLNB) in different clinical stages breast cancer patients being carried out with neoadjuvant chemotherapy (NAC), and the clinical significance of SLNB, we conducting this trial.MethodsOne hunderd and thirty-seven cases were enrolled in this clinical research from March 2003 to March 2007. All of the patients’ sentinel lymph nodes were detected with 99mTc-Dx and methylene blue. There were 61 patients with stage T1–2N0M0 carried SLNB without NAC (group A), 76 cases were carried out NAC 3–4 cycles before SLNB, including 39 T2–4N0–1M0 cases (group B) and 27 T2–4N2–3M0 cases (group C). The success and false negative rate of SLNB were analysed with chi-square test.ResultsIn group A, the successful and false negative rate of SLNB were 92.31% (36/39), 8.57% (3/35), and in group B and C were 92.31% (36/39), 8.57% (3/35) and 74.07 % (20/27), 18.52 % (5/27), respectively. The successful rate of group C decreased and false negative rate increased significantly compared with group A and B (P < 0.05), but group A and B had no significant difference (P > 0.05).ConclusionThe SLNB can accurately predict lymph node status of axillary lymph node in N0–1 stage patients with NAC, but in N2–3 stage patients the success rate decreased and false rate increased negative significantly. More... »

PAGES

521-523

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10330-013-1251-6

DOI

http://dx.doi.org/10.1007/s10330-013-1251-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1001085806


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.413606.6", 
          "name": [
            "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Juan", 
        "id": "sg:person.0742424175.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742424175.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.413606.6", 
          "name": [
            "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wu", 
        "givenName": "Xinhong", 
        "id": "sg:person.01124765775.48", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124765775.48"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.413606.6", 
          "name": [
            "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Feng", 
        "givenName": "Yaojun", 
        "id": "sg:person.015505600225.50", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015505600225.50"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.413606.6", 
          "name": [
            "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Yuan", 
        "givenName": "Feng", 
        "id": "sg:person.01302651555.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302651555.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China", 
          "id": "http://www.grid.ac/institutes/grid.413606.6", 
          "name": [
            "Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fan", 
        "givenName": "Wei", 
        "id": "sg:person.01125143301.14", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125143301.14"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s10330-005-0444-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008550728", 
          "https://doi.org/10.1007/s10330-005-0444-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10434-001-0013-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026261456", 
          "https://doi.org/10.1007/s10434-001-0013-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf02984543", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035412867", 
          "https://doi.org/10.1007/bf02984543"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-010-0973-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050817536", 
          "https://doi.org/10.1007/s10549-010-0973-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2013-11", 
    "datePublishedReg": "2013-11-01", 
    "description": "ObjectiveWe aimed to study the success and false negative rate of sentinel lymph node biopsy (SLNB) in different clinical stages breast cancer patients being carried out with neoadjuvant chemotherapy (NAC), and the clinical significance of SLNB, we conducting this trial.MethodsOne hunderd and thirty-seven cases were enrolled in this clinical research from March 2003 to March 2007. All of the patients\u2019 sentinel lymph nodes were detected with 99mTc-Dx and methylene blue. There were 61 patients with stage T1\u20132N0M0 carried SLNB without NAC (group A), 76 cases were carried out NAC 3\u20134 cycles before SLNB, including 39 T2\u20134N0\u20131M0 cases (group B) and 27 T2\u20134N2\u20133M0 cases (group C). The success and false negative rate of SLNB were analysed with chi-square test.ResultsIn group A, the successful and false negative rate of SLNB were 92.31% (36/39), 8.57% (3/35), and in group B and C were 92.31% (36/39), 8.57% (3/35) and 74.07 % (20/27), 18.52 % (5/27), respectively. The successful rate of group C decreased and false negative rate increased significantly compared with group A and B (P < 0.05), but group A and B had no significant difference (P > 0.05).ConclusionThe SLNB can accurately predict lymph node status of axillary lymph node in N0\u20131 stage patients with NAC, but in N2\u20133 stage patients the success rate decreased and false rate increased negative significantly.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10330-013-1251-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1032171", 
        "issn": [
          "2095-9621", 
          "1613-9089"
        ], 
        "name": "The Chinese-German Journal of Clinical Oncology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "12"
      }
    ], 
    "keywords": [
      "sentinel lymph node biopsy", 
      "neoadjuvant chemotherapy", 
      "breast cancer patients", 
      "group A", 
      "stage patients", 
      "cancer patients", 
      "clinical significance", 
      "false negative rate", 
      "ResultsIn group A", 
      "axillary sentinel lymph", 
      "lymph node biopsy", 
      "lymph node status", 
      "sentinel lymph nodes", 
      "T1-2N0M0", 
      "chi-square test", 
      "negative rate", 
      "axillary lymph", 
      "node biopsy", 
      "sentinel lymph", 
      "node status", 
      "lymph nodes", 
      "group B", 
      "group C", 
      "patients", 
      "clinical research", 
      "success rate", 
      "chemotherapy", 
      "significant differences", 
      "lymph", 
      "biopsy", 
      "successful rate", 
      "cases", 
      "rate", 
      "trials", 
      "significance", 
      "hunderd", 
      "status", 
      "ObjectiveWe", 
      "T2", 
      "N0", 
      "differences", 
      "success", 
      "test", 
      "nodes", 
      "cycle", 
      "research", 
      "false rate", 
      "N2", 
      "different clinical stages breast cancer patients", 
      "clinical stages breast cancer patients", 
      "stages breast cancer patients", 
      "MethodsOne hunderd", 
      "stage T1\u20132N0M0", 
      "NAC 3"
    ], 
    "name": "The clinical significance of axillary sentinel lymph node biopsy in different clinical stages breast cancer patients after neoadjuvant chemotherapy", 
    "pagination": "521-523", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1001085806"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10330-013-1251-6"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10330-013-1251-6", 
      "https://app.dimensions.ai/details/publication/pub.1001085806"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:29", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_601.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10330-013-1251-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1251-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1251-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1251-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10330-013-1251-6'


 

This table displays all metadata directly associated to this object as RDF triples.

156 TRIPLES      22 PREDICATES      84 URIs      72 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10330-013-1251-6 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N19d74fb4966f496fa67af4624e610868
4 schema:citation sg:pub.10.1007/bf02984543
5 sg:pub.10.1007/s10330-005-0444-z
6 sg:pub.10.1007/s10434-001-0013-9
7 sg:pub.10.1007/s10549-010-0973-1
8 schema:datePublished 2013-11
9 schema:datePublishedReg 2013-11-01
10 schema:description ObjectiveWe aimed to study the success and false negative rate of sentinel lymph node biopsy (SLNB) in different clinical stages breast cancer patients being carried out with neoadjuvant chemotherapy (NAC), and the clinical significance of SLNB, we conducting this trial.MethodsOne hunderd and thirty-seven cases were enrolled in this clinical research from March 2003 to March 2007. All of the patients’ sentinel lymph nodes were detected with 99mTc-Dx and methylene blue. There were 61 patients with stage T1–2N0M0 carried SLNB without NAC (group A), 76 cases were carried out NAC 3–4 cycles before SLNB, including 39 T2–4N0–1M0 cases (group B) and 27 T2–4N2–3M0 cases (group C). The success and false negative rate of SLNB were analysed with chi-square test.ResultsIn group A, the successful and false negative rate of SLNB were 92.31% (36/39), 8.57% (3/35), and in group B and C were 92.31% (36/39), 8.57% (3/35) and 74.07 % (20/27), 18.52 % (5/27), respectively. The successful rate of group C decreased and false negative rate increased significantly compared with group A and B (P < 0.05), but group A and B had no significant difference (P > 0.05).ConclusionThe SLNB can accurately predict lymph node status of axillary lymph node in N0–1 stage patients with NAC, but in N2–3 stage patients the success rate decreased and false rate increased negative significantly.
11 schema:genre article
12 schema:inLanguage en
13 schema:isAccessibleForFree false
14 schema:isPartOf N08820efc69dc4bdc8f48abdc3b597ceb
15 Nadbdccff249c42118e6be9d6da9479e7
16 sg:journal.1032171
17 schema:keywords MethodsOne hunderd
18 N0
19 N2
20 NAC 3
21 ObjectiveWe
22 ResultsIn group A
23 T1-2N0M0
24 T2
25 axillary lymph
26 axillary sentinel lymph
27 biopsy
28 breast cancer patients
29 cancer patients
30 cases
31 chemotherapy
32 chi-square test
33 clinical research
34 clinical significance
35 clinical stages breast cancer patients
36 cycle
37 differences
38 different clinical stages breast cancer patients
39 false negative rate
40 false rate
41 group A
42 group B
43 group C
44 hunderd
45 lymph
46 lymph node biopsy
47 lymph node status
48 lymph nodes
49 negative rate
50 neoadjuvant chemotherapy
51 node biopsy
52 node status
53 nodes
54 patients
55 rate
56 research
57 sentinel lymph
58 sentinel lymph node biopsy
59 sentinel lymph nodes
60 significance
61 significant differences
62 stage T1–2N0M0
63 stage patients
64 stages breast cancer patients
65 status
66 success
67 success rate
68 successful rate
69 test
70 trials
71 schema:name The clinical significance of axillary sentinel lymph node biopsy in different clinical stages breast cancer patients after neoadjuvant chemotherapy
72 schema:pagination 521-523
73 schema:productId N26b11a3dfa0c462ca48d300b9cb8014c
74 N3e94a4dbe1eb481bb74c06bc58e2884f
75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001085806
76 https://doi.org/10.1007/s10330-013-1251-6
77 schema:sdDatePublished 2022-01-01T18:29
78 schema:sdLicense https://scigraph.springernature.com/explorer/license/
79 schema:sdPublisher N64c55a86a0474f79b4251a4ca8b87af0
80 schema:url https://doi.org/10.1007/s10330-013-1251-6
81 sgo:license sg:explorer/license/
82 sgo:sdDataset articles
83 rdf:type schema:ScholarlyArticle
84 N08820efc69dc4bdc8f48abdc3b597ceb schema:volumeNumber 12
85 rdf:type schema:PublicationVolume
86 N19d74fb4966f496fa67af4624e610868 rdf:first sg:person.0742424175.37
87 rdf:rest N24daa6d3570345039fc57814e5bcb281
88 N24daa6d3570345039fc57814e5bcb281 rdf:first sg:person.01124765775.48
89 rdf:rest N9227c73957c5405182e208ca371e0b83
90 N26b11a3dfa0c462ca48d300b9cb8014c schema:name dimensions_id
91 schema:value pub.1001085806
92 rdf:type schema:PropertyValue
93 N3e94a4dbe1eb481bb74c06bc58e2884f schema:name doi
94 schema:value 10.1007/s10330-013-1251-6
95 rdf:type schema:PropertyValue
96 N64c55a86a0474f79b4251a4ca8b87af0 schema:name Springer Nature - SN SciGraph project
97 rdf:type schema:Organization
98 N9227c73957c5405182e208ca371e0b83 rdf:first sg:person.015505600225.50
99 rdf:rest Ncec6d48dd8f34cce93a55897942aa76f
100 Nadbdccff249c42118e6be9d6da9479e7 schema:issueNumber 11
101 rdf:type schema:PublicationIssue
102 Nb96e83b881e04455b9d8eb06ab938830 rdf:first sg:person.01125143301.14
103 rdf:rest rdf:nil
104 Ncec6d48dd8f34cce93a55897942aa76f rdf:first sg:person.01302651555.09
105 rdf:rest Nb96e83b881e04455b9d8eb06ab938830
106 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
107 schema:name Medical and Health Sciences
108 rdf:type schema:DefinedTerm
109 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
110 schema:name Oncology and Carcinogenesis
111 rdf:type schema:DefinedTerm
112 sg:journal.1032171 schema:issn 1613-9089
113 2095-9621
114 schema:name The Chinese-German Journal of Clinical Oncology
115 schema:publisher Springer Nature
116 rdf:type schema:Periodical
117 sg:person.01124765775.48 schema:affiliation grid-institutes:grid.413606.6
118 schema:familyName Wu
119 schema:givenName Xinhong
120 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01124765775.48
121 rdf:type schema:Person
122 sg:person.01125143301.14 schema:affiliation grid-institutes:grid.413606.6
123 schema:familyName Fan
124 schema:givenName Wei
125 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01125143301.14
126 rdf:type schema:Person
127 sg:person.01302651555.09 schema:affiliation grid-institutes:grid.413606.6
128 schema:familyName Yuan
129 schema:givenName Feng
130 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01302651555.09
131 rdf:type schema:Person
132 sg:person.015505600225.50 schema:affiliation grid-institutes:grid.413606.6
133 schema:familyName Feng
134 schema:givenName Yaojun
135 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015505600225.50
136 rdf:type schema:Person
137 sg:person.0742424175.37 schema:affiliation grid-institutes:grid.413606.6
138 schema:familyName Xu
139 schema:givenName Juan
140 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0742424175.37
141 rdf:type schema:Person
142 sg:pub.10.1007/bf02984543 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035412867
143 https://doi.org/10.1007/bf02984543
144 rdf:type schema:CreativeWork
145 sg:pub.10.1007/s10330-005-0444-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1008550728
146 https://doi.org/10.1007/s10330-005-0444-z
147 rdf:type schema:CreativeWork
148 sg:pub.10.1007/s10434-001-0013-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026261456
149 https://doi.org/10.1007/s10434-001-0013-9
150 rdf:type schema:CreativeWork
151 sg:pub.10.1007/s10549-010-0973-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050817536
152 https://doi.org/10.1007/s10549-010-0973-1
153 rdf:type schema:CreativeWork
154 grid-institutes:grid.413606.6 schema:alternateName Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China
155 schema:name Department of Breast Cancer, Hubei Cancer Hospital, 430079, Wuhan, China
156 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...